Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for SCY-247 in Fungal infections. The expected timing is based on the latest available company guidance and may change.
12/18/24- Initiated dosing. 9/30/25- Ph1 positive results from SAD & MAD reported. 11/05/25:- After positive Ph1 SAD/MAD, Q1 2026 IV Ph1 start; Ph2 proof-of-concept data expected 2026. 01/21/26:- Received FDA QIDP and Fast Track for SCY-247. Still plans 2026 IV Ph1, oral Ph2, IC proof-of-concept data. 01/28/26:- IMARI 2026 oral and poster presentations planned on SCY-247 antifungal activity and early clinical profile. 02/26/26:- First participants dosed in IV Ph1 SAD/MAD; trial results expected in 2026. 03/04/26:- Expanded access program planned H1 2026; IV Ph1 topline data H2 2026; IC Ph2 proof-of-concept planned 2026. 05/11/26:- IV Ph1 topline data now expected Q3 2026; oral SCY-247 expanded access program now accepting requests. 08/10/26:- IV Ph1 dosing completed. Topline data remain expected in Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.